CoChat
Sign Up
Cited by 128

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Inhibition of HSV-1 Replication by Gene Editing Strategy

Roehm, Pamela C., Shekarabi, Masoud, Wollebo, Hassen S., Bellizzi, Anna, He, Lifan, Salkind, Julian, Khalili, Kamel·2016·Scientific Reports
DOI 10.1038/srep23146PMC PMC4827394
Open this paper in CoChat — free account

Abstract

HSV-1 induced illness affects greater than 85% of adults worldwide with no permanent curative therapy. We used RNA-guided CRISPR/Cas9 gene editing to specifically target for deletion of DNA sequences of the HSV-1 genome that span the region directing expression of ICP0, a key viral protein that stimulates HSV-1 gene expression and replication. We found that CRISPR/Cas9 introduced InDel mutations into exon 2 of the ICP0 gene profoundly reduced HSV-1 infectivity in permissive human cell culture models and protected permissive cells against HSV-1 infection. CRISPR/Cas9 mediated targeting ICP0 prevented HSV-1-induced disintegration of promonocytic leukemia (PML) nuclear bodies, an intracellular event critical to productive HSV-1 infection that is initiated by interaction of the ICP0 N-terminus with PML. Combined treatment of cells with CRISPR targeting ICP0 plus the immediate early viral proteins, ICP4 or ICP27, completely abrogated HSV-1 infection. We conclude that RNA-guided CRISPR/Cas9 can be used to develop a novel, specific and efficacious therapeutic and prophylactic platform for targeted viral genomic ablation to treat HSV-1 diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep23146

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CRISPR/Cas9 introduces mutations in ICP0 gene and reduces HSV-1 replication. (A) Schematic representation of HSV-1 ICP0 genomic region showing exon II and the ring domain. The positions and nucleotide composition of 2A, 2B and 2C targets including PAM (marked in green) are shown. The positions of various primers (P) used in PCR amplification are illustrated. (B) Gel analysis of DNA fragments amplified by primers P3 and P2 (shown in A) in L7 cells expressing Cas9 (control) or Cas9 plus gRNAs 2A and 2C. The positions of an expected 552 bp amplicon and a smaller DNA fragment of 217 bp caused by cleavage of exon II DNA at targets (A,C), and amplification of the remaining fragments after ligation are shown. (C) Sequence traces of the 217 bp cloned fragment (shown in B) illustrating a blunt end-joining of the two ends of the cleaved exon II DNA after excision of 355 bp. D. DNA gel analysis illustrating amplicons using P3 and P4 primers from several clonal cells (named InDels 1-3) expressing Cas9/gRNA 2A or the control cells with no gRNA 2A. (E) DNA sequencing identified nucleotide insertions (as depicted by black arrowheads) in clones InDel 1 and 2, and insertion of 191 bp DNA in clones InDel 3. The red arrowhead points to the cleavage sites. (F) Representative confocal images of L7 cells (control) and its subclones InDel 3 (shown in E) expressing Cas9/gRNA 2A after immunostaining with an antibody against ICP0. Green is indicative of expression of GFP by HSV-1 and DAPI (blue) depicts the nuclei of the cells. (G) Viral production assay demonstrating the titer of ΔICP0-HSV-1 in the supernatant of parental L7 cells (control) endogenously expressing ICP0 or in InDel 3, InDel 2 (shown in E).
Figure 1 CRISPR/Cas9 introduces mutations in ICP0 gene and reduces HSV-1 replication. (A) Schematic representation of HSV-1 ICP0 genomic region showing exon II and the ring domain. The positions and nucleotide composition of 2A, 2B and 2C targets including PAM (marked in green) are shown. The positions of various primers (P) used in PCR amplification are illustrated. (B) Gel analysis of DNA fragments amplified by primers P3 and P2 (shown in A) in L7 cells expressing Cas9 (control) or Cas9 plus gRNAs 2A and 2C. The positions of an expected 552 bp amplicon and a smaller DNA fragment of 217 bp caused by cleavage of exon II DNA at targets (A,C), and amplification of the remaining fragments after ligation are shown. (C) Sequence traces of the 217 bp cloned fragment (shown in B) illustrating a blunt end-joining of the two ends of the cleaved exon II DNA after excision of 355 bp. D. DNA gel analysis illustrating amplicons using P3 and P4 primers from several clonal cells (named InDels 1-3) expressing Cas9/gRNA 2A or the control cells with no gRNA 2A. (E) DNA sequencing identified nucleotide insertions (as depicted by black arrowheads) in clones InDel 1 and 2, and insertion of 191 bp DNA in clones InDel 3. The red arrowhead points to the cleavage sites. (F) Representative confocal images of L7 cells (control) and its subclones InDel 3 (shown in E) expressing Cas9/gRNA 2A after immunostaining with an antibody against ICP0. Green is indicative of expression of GFP by HSV-1 and DAPI (blue) depicts the nuclei of the cells. (G) Viral production assay demonstrating the titer of ΔICP0-HSV-1 in the supernatant of parental L7 cells (control) endogenously expressing ICP0 or in InDel 3, InDel 2 (shown in E).CC BY · PubMed Central
Figure 2 CRISPR/Cas9 by targeting ICP0 expression restores association of PML bodies in L7 cells. Immunostaining analysis of PML bodies in control, uninfected L7 cells shows the appearance of punctate staining of PML bodies within the nuclei of the cells (lower panel). DAPI staining of nuclei (blue) is shown in the right panels. Infection of Vero L7 cells expressing Cas9 at low MOI with HSV-1/GFP shows complete destruction of the PML and robust replication of HSV-1/GFP as shown in green (middle panels). In L7 cells expressing Cas9/gRNA 2A infection with HSV-1/GFP failed to disrupt formation of punctate PML in the nuclei and significantly reduced the level of viral replication detected in the cells (green, top panels).
Figure 2 CRISPR/Cas9 by targeting ICP0 expression restores association of PML bodies in L7 cells. Immunostaining analysis of PML bodies in control, uninfected L7 cells shows the appearance of punctate staining of PML bodies within the nuclei of the cells (lower panel). DAPI staining of nuclei (blue) is shown in the right panels. Infection of Vero L7 cells expressing Cas9 at low MOI with HSV-1/GFP shows complete destruction of the PML and robust replication of HSV-1/GFP as shown in green (middle panels). In L7 cells expressing Cas9/gRNA 2A infection with HSV-1/GFP failed to disrupt formation of punctate PML in the nuclei and significantly reduced the level of viral replication detected in the cells (green, top panels).CC BY · PubMed Central
Figure 3 Human TC620 cells expressing Cas9/gRNAs does not support HSV-1 replication. (A) Western blot analysis of protein extracts for detection of ICP0 in TC620 human olidodendroglioma cells and its subclones expressing Cas9 or Cas9/gRNA 2A (clones 6 and 10). Expression of 110 kDa ICP0 is detected in the control cells and cells expressing Cas9, but severely reduced in clones 6 and 10. Expression of housekeeping tubulin is shown. (B) Representative plaque assay using the supernatant from HSV-1/GFP infected control TC620 or clones 6 and 10 at two different dilutions showing a drastic decrease in the number of plaques as a result of suppression of ICP0 by Cas9/gRNA editing of the infected cells. (D) Quantification of HSV-1 production by plaque assay shows drastic suppression of the viral production in TC620 cells with continuous production of Cas9 plus gRNA 2A.
Figure 3 Human TC620 cells expressing Cas9/gRNAs does not support HSV-1 replication. (A) Western blot analysis of protein extracts for detection of ICP0 in TC620 human olidodendroglioma cells and its subclones expressing Cas9 or Cas9/gRNA 2A (clones 6 and 10). Expression of 110 kDa ICP0 is detected in the control cells and cells expressing Cas9, but severely reduced in clones 6 and 10. Expression of housekeeping tubulin is shown. (B) Representative plaque assay using the supernatant from HSV-1/GFP infected control TC620 or clones 6 and 10 at two different dilutions showing a drastic decrease in the number of plaques as a result of suppression of ICP0 by Cas9/gRNA editing of the infected cells. (D) Quantification of HSV-1 production by plaque assay shows drastic suppression of the viral production in TC620 cells with continuous production of Cas9 plus gRNA 2A.CC BY · PubMed Central
Figure 4 Lentivirus (LV) mediated Cas9/gRNA delivery suppresses HSV-1 infection during the lytic cycle and prevents uninfected cells from new infection. (A) Western blot analysis of protein extracts from TC260 cells that endogenously express Cas9 and are infected with HSV-1/GFP for 24 hours and thereafter treated with lentivirus expressing gRNAs 2A, 2B or both and harvested 48 hours later for protein extraction. The positions of ICP0, ICP8, glycoprotein C Cas9 and α-tubulin are shown. (B,C) illustrate results from plaque assay in which cells treated with LVgRNA 2A or LVgRNA 2B showed a drastic decrease in virus production. (D) Confocal immunofluorescent evaluation of HSV-1/GFP replication in TC620 cells that were treated with vector (LV) LVCas9, LVCas9 plus LVgRNA 2A, LVCas9 plus gRNA 2B and LVCas9 plus LVgRNA 2A and 2B at 48 hours prior to HSV-1 infection. A decrease in the replication of HSV-1/GFP is shown in green. (D) Western blot analysis of protein extracts from the infected cells as described above. (E) Plaque assay showing a decrease in the titer of the virus released upon HSV-1 infection of cells that were pre-treated with LV producing Cas9 and gRNAs as depicted.
Figure 4 Lentivirus (LV) mediated Cas9/gRNA delivery suppresses HSV-1 infection during the lytic cycle and prevents uninfected cells from new infection. (A) Western blot analysis of protein extracts from TC260 cells that endogenously express Cas9 and are infected with HSV-1/GFP for 24 hours and thereafter treated with lentivirus expressing gRNAs 2A, 2B or both and harvested 48 hours later for protein extraction. The positions of ICP0, ICP8, glycoprotein C Cas9 and α-tubulin are shown. (B,C) illustrate results from plaque assay in which cells treated with LVgRNA 2A or LVgRNA 2B showed a drastic decrease in virus production. (D) Confocal immunofluorescent evaluation of HSV-1/GFP replication in TC620 cells that were treated with vector (LV) LVCas9, LVCas9 plus LVgRNA 2A, LVCas9 plus gRNA 2B and LVCas9 plus LVgRNA 2A and 2B at 48 hours prior to HSV-1 infection. A decrease in the replication of HSV-1/GFP is shown in green. (D) Western blot analysis of protein extracts from the infected cells as described above. (E) Plaque assay showing a decrease in the titer of the virus released upon HSV-1 infection of cells that were pre-treated with LV producing Cas9 and gRNAs as depicted.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 42

  1. Whitley, R. J. & Roizman B. Herpes simplex virus infections. Lancet 357, 1513–1518. · DOI
  2. Xu, F. et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296, 964–973. · DOI
  3. Baringer, J. R. Herpes Virus Encephalitis. In: Davis, L. E., Kennedy, P. G. E. (eds) Infectious diseases of the nervous system. Butterworth-Heinemann. Oxford pp. 139–164 (2000).
  4. Kennedy, P. G. E. & Chaudhuri. A. Herpes simplex encephalitis. J. Neurol. Neurosurg. Psychiatry 73, 237–238 (2002). · DOI
  5. Kennedy, P. G. E. & Steiner, I. Recent issues in herpes simplex encephalitis. J. Neurovirol. 19, 346–350 (2013). · DOI
  6. Westerberg, B. D., Atashband, S. & Kozak, F. K. A systematic review of the incidence of sensorineural hearing loss in neonates exposed to herpes simplex virus (HSV). Int. J. Pediatr. Otorhinolaryngol. 72, 931–937 (2008). · DOI
  7. Gilden, D. H., Mahalingam, R., Cohrs, R. J. & Tyler, K. L. Herpesvirus infections of the nervous system. Nature Clin. Practice 3, 82–94 (2007). · DOI
  8. Fraser, N. W., Lawrence, W. C., Wroblewska, Z., Gilden, D. H. & Koprowski, H. Herpes simplex type 1 DNA in human brain tissue. Proc Natl Acad Sci USA 78, 6461–6465 (1981) · DOI
  9. Mahalingam, R. Wellish, M. C., Dueland, A. N., Cohrs, R. J. & Gilden, D. H. Localization of herpes simplex virus and varicella zoster virus DNA in human ganglia. Ann. Neurol. 31, 444–448 (1992). · DOI
  10. Izumi, K. M., McKelvey, A. M., Devi-Rao, G., Wagner, E. K. & Stevens, J. G. Molecular and biological characterization of a type 1 herpes simplex virus (HSV-1) specifically deleted for expression of the latency-associated transcript (LAT). Microb. Pathog. 7, 121–134. · DOI
  11. Kang, W., Mukerjee, R. & Fraser, N. W. Establishment and maintenance of HSV latent infection is mediated through correct splicing of the LAT primary transcript. Virology 312, 233–244 (2003). · DOI
  12. Perng, G. C. et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 287, 1500–1503. · DOI
  13. Stevens, J. G., Wagner, E. K., Devi-Rao, G. B., Cook, M. L. & Feldman, L. T. RNA complemenatary to a herpesvirus alpha gene mRNA is prominent in latenly infected neurons. Science 235, 1056–1059 (1987). · DOI
  14. Belshe, R. B. et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366, 34–43 (2012). · DOI
  15. Garneau, J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67–71 (2010). · DOI
  16. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109, 15539–15540 (2012). · DOI · Paper page
  17. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013). · DOI · Paper page
  18. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013). · DOI · Paper page
  19. Hu, W. et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 111, 11461–11466 (2014). · DOI · Paper page
  20. Wollebo, H. S. et al. CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection. PLoS One 10, e0136046 (2015) · DOI
  21. Yuen, K. S. et al. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J. Gen. Virol. 96, 626–636 (2015). · DOI
  22. Delboy, M. G. & Nicola, A. V. A pre-immediate early role for tegument ICP0 in the proteasome-dependent entry of herpes simplex virus. J. Virol. 85, 5910–5918 (2011). · DOI
  23. Boutell, C. & Everett, R. D. Regulation of alphaherpesvirus infections by the ICP0 family of proteins. J. Gen. Virol. 94, 465–481 (2013). · DOI
  24. Hagglund, R. & Roizman, B. Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1. J. Virol. 78, 2169–2178 (2004). · DOI
  25. Samaniego, L. A., Wu, N. & DeLuca, N. A. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 71, 4614–4625 (1997). · DOI
  26. Halford, W. P. et al. ICP0 antagonizes Stat 1-dependent repression of herpes simples virus: implications for the regulation of viral latency. Virol. J. 3, 44 (2006). · DOI
  27. Halford, W. P., Püschel, R. & Rakowski, B. Herpes simplex virus 2 ICP0- mutant viruses are avirulent and immunogenic: implications for a genital herpes virus vaccine. PloS One 5, e12251 (2010). · DOI
  28. Sahin, U., Lallemand-Breitenbach, V. & de Thé, H. PML nuclear bodies: regulation, function and therapeutic perspectives. J. Pathol. 234, 289–291 (2014). · DOI
  29. Wang, S., Long, J. & Zheng, C. F. The potential link between PML NBs and ICP0 in regulating lytic and latent infection of HSV-1. Protein Cell 3, 372–382 (2012). · DOI
  30. Cuchet-Lourenco, D., Vanni, E., Glass, M., Orr, A. & Everett, R. D. Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-dependent degradation. J. Virol. 86, 11209–11222 (2012). · DOI
  31. Everett, R. D. et al. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80, 7995–8005 (2006). · DOI
  32. Merrill, J. E. & Matsushima, K. Production of and response to interleukin 1 by cloned human oligodendroglioma cell lines. J. Biol. Regul. Homeost. Agents 2, 77–86 (1988).
  33. Challberg, M. D. A method for identifying the viral genes required for herpesvirus DNA replication. Proc. Natl. Acad. Sci. USA 83, 9094–9098 (1986). · DOI
  34. Gao, M. & Knipe, D. M. Potential role for herpes simplex virus ICP8 DNA replication protein in stimulation of late gene expression. J. Virol. 65, 2666–2675 (1991). · DOI
  35. Tanguy Le Gac, N., Villani, G. & Boehmer, P. E. Herpes simplex virus type-1 single-strand DNA-binding protein (ICP8) enhances the ability of the viral DNA helicase-primase to unwind cisplatin-modified DNA. J. Biol. Chem. 273, 13801–13807 (1998). · DOI
  36. Friedman, H. M., Cohen, G. H., Eisenberg, R. J., Seidel, C. A. & Cines, D. B. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature 309, 633–635 (1984). · DOI
  37. Chen, J. & Silverstein, S. Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression. J. Virol. 66, 2916–2927 (1992). · DOI
  38. Knipe, D. M. & Cliffe, A. Chromatin control of herpes simplex virus lytic and latent infection. Nature Rev. 6, 211–221 (2008).
  39. Horvath, P. & Barrangou, R. CRISPR/Cas9, the immune system of bacteria and archaea. Science 327, 167–170 (2010). · DOI
  40. Shekarabi, M. et al. Mutations in the nervous system—specific HSN2 exon of WNK1 cause heredity sensory neuropathy type II. J. Clin. Invest. 118, 2496–2505 (2008).
  41. Shekarabi, M. & Kennedy, T. E. The netrin-1 receptor DCC promotes filopodia formation and cell spreading by activating Cdc42 and Rac1. Mol. Cell. Neurosci. 19, 1–17 (2002). · DOI
  42. Cai, W. & Schaffer, P. A. Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early and late genes in productively infected cells. J. Virol. 66, 2904–2915 (1992). · DOI

Cited by

Sorted by citations

See all 128

Metadata

Authors
Roehm, P. C., Shekarabi, M., Wollebo, H. S., Bellizzi, A., He, L., Salkind, J., & Khalili, K.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2016-04-11
Volume
6
Issue
1
ISSN
2045-2322
DOI
10.1038/srep23146
PMC
PMC4827394
Cited by
128
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review